<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256213</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-CE108b</org_study_id>
    <secondary_id>2019-002271-34</secondary_id>
    <nct_id>NCT04256213</nct_id>
  </id_info>
  <brief_title>COL Immunotherapy Before Radiochimio + Ipilimumab</brief_title>
  <acronym>COLIBRI</acronym>
  <official_title>A Multicenter, Pilot Study Evaluating Immune Impact and Safety of Nivolumab in Combination With Ipilimumab (Immune Combination) Before Initial RT-CT Treatment for Cervix Cancer.: the French GINECO - COLIBRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single arm pilot study evaluating the biological impact of &quot;Nivolumab&#xD;
      + Ipilimumab&quot; in patients with cervical squamous cell carcinoma requiring RT-CT as initial&#xD;
      therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of COLIBRI is to evaluate the evolution of the CD8+/FOXP3+ ratio of lymphocytes in&#xD;
      pre- versus post-treatment biopsies in patients treated with a combination of Nivolumab and&#xD;
      Ipilimumab in a pilot study, just before starting standard RT-CT.&#xD;
&#xD;
      The study will also assess tolerability, Objective Response Rate, clinical activity and&#xD;
      biological (dynamic) changes of the immune micro environment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD8+/FOXP3+ relative change of lymphocytes from pre to post treatment biopsies</measure>
    <time_frame>Baseline, before RT-CT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 100-days after end of treatment or until initiation of alternative cancer therapy</time_frame>
    <description>Assessed by CTCAE 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>1week before RT-CT, 4 weeks after RT-CT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cervix Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab and Ipilimumab</intervention_name>
    <description>Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT&#xD;
Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)</description>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically confirmed diagnosis of cervical squamous cell carcinoma stage IB3 to IVA,&#xD;
        (FIGO 2018)&#xD;
&#xD;
          -  Patients requiring RT-CT therapy as standard of care&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Patient accepting to undergo a new cervix biopsy&#xD;
&#xD;
          -  Adequate marrow function:&#xD;
&#xD;
               -  White blood cell (WBC) &gt;2000/mm3 (stable off any growth factor within 4 weeks of&#xD;
                  first study drug administration)&#xD;
&#xD;
               -  Neutrophils &gt;1500/ mm3 (stable off any growth factor within 4 weeks of first&#xD;
                  study drug administration)&#xD;
&#xD;
               -  Platelets &gt; 100× 103/mm3 (transfusion to achieve this level is not permitted&#xD;
                  within 2 weeks of first study drug administration)&#xD;
&#xD;
               -  Hemoglobin &gt; 8 g/dL (transfusion to achieve this level is not permitted within 2&#xD;
                  weeks of first study drug administration)&#xD;
&#xD;
          -  Adequate other organ functions:&#xD;
&#xD;
               -  ALT and AST &lt; 3× institutional ULN&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5× institutional ULN (except subjects with Gilbert's Syndrome&#xD;
                  who must have normal direct bilirubin)&#xD;
&#xD;
               -  Normal thyroid function, subclinical hypothyroidism (thyroid-stimulating hormone&#xD;
                  [TSH] &lt; 10 mIU/mL) or have controlled hypothyroidism on appropriate thyroid&#xD;
                  supplementation&#xD;
&#xD;
               -  Serum creatinine &lt; 2× ULN or creatinine clearance (CrCl) &gt; 40 mL/min (measured&#xD;
                  using the Cockcroft-Gault formula or the MDRD formula for patients older than 65&#xD;
                  years-old&#xD;
&#xD;
          -  General Health as evidenced by PS ≤2&#xD;
&#xD;
          -  Covered by a medical insurance&#xD;
&#xD;
          -  Signed and dated informed consent form prior to any study-specific procedure.&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test For&#xD;
             females of reproductive potential: use of highly effective contraception and for at&#xD;
             least 5 months after administration of the last dose of nivolumab. A woman is&#xD;
             considered to be of childbearing potential if she is postmenarcheal, has not reached a&#xD;
             postmeno-pausal state (≥ 12 continuous months of amenorrhea with no identified cause&#xD;
             other than menopause), and has not undergone surgical sterilization (removal of&#xD;
             ovaries, fallopian tubes, and/or uterus).&#xD;
&#xD;
          -  All subjects must consent to allow the acquisition of blood samples, FFPE tumor&#xD;
             tissue, either a block or 15 to 20 unstained slides, and fresh tumor for performance&#xD;
             of correlative studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Patient concurrently using other approved or investigational antineoplastic agents.&#xD;
&#xD;
          -  Patient candidate for neo adjuvant CT before RT-CT&#xD;
&#xD;
          -  Any contraindication to nivolumab or ipilimumab treatments as per Nivolumab and&#xD;
             Ipilimumab Investigator's Brochure&#xD;
&#xD;
          -  Prior therapy with an immune checkpoint inhibitor&#xD;
&#xD;
          -  Prior history of other malignancies other than study disease (except for basal cell or&#xD;
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the&#xD;
             patient has been free of the disease for at least 3 years.&#xD;
&#xD;
          -  Immune-deficient status (patients with HIV, immunosuppressive treatment,&#xD;
             haematological malignancies, and previous organ transplantation)&#xD;
&#xD;
          -  History of any chronic hepatitis as evidenced by:&#xD;
&#xD;
               -  Positive test for hepatitis B surface antigen&#xD;
&#xD;
               -  Positive test for qualitative hepatitis C viral load (by polymerase chain&#xD;
                  reaction [PCR])&#xD;
&#xD;
        Note: Subjects with positive hepatitis C antibody and negative quantitative hepatitis C by&#xD;
        PCR are eligible. History of resolved hepatitis A virus infection is not an exclusion&#xD;
        criterion&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               -  Myocardial infarction or stroke/transient ischemic attack within the past 6&#xD;
                  months&#xD;
&#xD;
               -  Uncontrolled angina within the past 3 months&#xD;
&#xD;
               -  History of other clinically significant heart disease (eg, cardiomyopathy,&#xD;
                  congestive heart failure with New York Heart Association functional&#xD;
                  classification III-IV, pericarditis, significant pericardial effusion, or&#xD;
                  myocarditis)&#xD;
&#xD;
               -  Any history of clinically significant arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
               -  QT interval corrected for heart rate using Fridericia's formula (QTcF)&#xD;
                  prolongation &gt; 480 msec&#xD;
&#xD;
               -  Cardiovascular disease-related requirement for daily supplemental oxygen therapy&#xD;
&#xD;
          -  Subjects with known or suspected CNS metastases, untreated CNS metastases, are&#xD;
             excluded.&#xD;
&#xD;
        Note: However, subjects with controlled brain metastases will be allowed to enroll.&#xD;
        Controlled brain metastases are defined as no radiographic progression for at least 4 weeks&#xD;
        following radiation and/or surgical treatment (or 4 weeks of observation if no intervention&#xD;
        is clinically indicated), and off of steroids for at least 2 weeks, and no new or&#xD;
        progressive neurological signs and symptoms.&#xD;
&#xD;
        • Patients requiring concomitant treatment with therapeutic doses of anticoagulants will&#xD;
        not be eligible for this clinical trial.&#xD;
&#xD;
        Note: Patients treated with low dose of anticoagulants for thrombo-embolic events&#xD;
        prophylaxis are allowed.&#xD;
&#xD;
        • Any major surgery within 4 weeks of study drug administration. Subjects must have&#xD;
        recovered from the effects of major surgery or significant traumatic injury at least 14&#xD;
        days before the first dose of study drug.&#xD;
&#xD;
        Note: Pelvic and aortic dissection is not considered as traumatic surgery, and therefore&#xD;
        can be performed if clinically indicated.&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Note: Subjects with skin&#xD;
             disorders (such as vitiligo, psoriasis or alopecia), type I diabetes mellitus,&#xD;
             hypothyroidism only requiring hormone replacement or conditions not expected to recur&#xD;
             in the absence of an external trigger are permitted to enroll.&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration.&#xD;
&#xD;
        Note: Inhaled or topical steroids, and adrenal replacement doses are permitted in the&#xD;
        absence of active autoimmune disease.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle RAY-COQUARD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses - Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75278</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie, CARIO-HPCA</name>
      <address>
        <city>Plérin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud IUCT-O</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervix cancer</keyword>
  <keyword>Immune combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

